Clinical Trials Sponsored by Centocor Research & Development, Inc.

Total 405 results

Centocor Research & Development, Inc.

Completed

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis (PHOENIX1)

Psoriasis

United States, Belgium, Canada
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer

United States, United Kingdom, Belgium, Russian Federation
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Columbia University
Centocor Research & Development, Inc.

Completed

Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients

Lupus Nephritis

United States
FDA Office of Orphan Products Development
Centocor, Inc.

Completed

Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease

Crohn's Disease
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Terminated

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Myelodysplastic Syndromes | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

Anemia | Chronic Kidney Disease
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Withdrawn

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease

Anemia | Chronic Kidney Disease
Maier, Lisa, M.D.
Centocor, Inc.; National Center for Research Resources (NCRR)

Terminated

Beryllium Infliximab Study: Clinical Interventional Trial (BISCIT)

Berylliosis | Beryllium Disease

United States
Belgian Inflammatory Bowel Disease Research and...
Schering-Plough; Centocor BV

Completed

Top Down Versus Step Up Strategies in Crohn's Disease

Crohn's Disease

Belgium
Janssen Research & Development, LLC
Innovaderm Research Inc.

Completed

Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling

Psoriasis Vulgaris

Canada
BioNTech Research & Development, Inc.

Terminated

Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy

Pancreatic Carcinoma | Tumors That Express CA 19-9

United States
National Development and Research Institutes, Inc.

Unknown

The Staying Safe Intervention (Ssafe)

Hepatitis C | Opioid Use

United States
National Development and Research Institutes, Inc.

Unknown

Increasing HIV Testing in Urban Emergency Departments Via Mobile Technology

HIV Testing

United States
BioNTech Research & Development, Inc.

Recruiting

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Pancreatic Cancer

United States
National Development and Research Institutes, Inc.

Unknown

Mobile Intervention for Young Opioid Users

Opioid-Related Disorders

United States
Janssen Research & Development, LLC
Eisai Inc.

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux

United States, United Kingdom, Poland, Germany
Janssen Research & Development, LLC
Genentech, Inc.

Completed

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX)

Carcinoma, Non-Small-Cell Lung

France, United States, Spain, Hungary, Poland
Janssen Research & Development, LLC
Eisai Inc.

Completed

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Gastroesophageal Reflux Disease (GERD)

United States, Poland, United Kingdom, Belgium, Brazil
National Development and Research Institutes, Inc.

Unknown

Applying Web Technology to Buprenorphine Treatment

Adult Opioid-Dependence

United States
Criterium, Inc.
EMD Serono Research & Development Institute, Inc.

Terminated

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Advanced Non-Small Cell Lung Cancer With MET Mutations

United States
Primex Clinical Laboratories, Inc.
Research & Development Institute, Inc.

Unknown

Evaluation of Primex's PGX Assay to Assess the Clinical Utility of Pharmacogenomics

Patients on Medications Metabolized Via CYP450

United States
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Switzerland, France
Zona Health, Inc
Research & Development Concierge Company

Terminated

A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients

Hypertension, Systolic

United States
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Participants With Advanced Malignancies

Neoplasms

France, Belgium
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
Glaucoma Research & Education Group
PharmaLogic Development, Inc.

Unknown

The Efficacy of Selective Laser Trabeculoplasty

Primary Open Angle Glaucoma | Ocular Hypertension | Pigment Dispersion Glaucoma | Pseudo-Exfoliative Glaucoma

United States
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Active, not recruiting

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (CULMINATE)

Leukemia, Myeloid, Acute

Switzerland, Israel, Spain, France, Turkey, Italy, Australia, Brazil, Russian Federation
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Active, not recruiting

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ELEVATE)

Leukemia, Myeloid, Acute

Canada, United States, Poland, Switzerland, Germany
Glaucoma Research & Education Group
PharmaLogic Development, Inc.

Completed

Effectiveness of a Procedure for Previously Failed Glaucoma Surgery

Glaucoma

United States
Johnson & Johnson Pharmaceutical Research & Development...
Bedford Research Corporation, Inc.

Completed

Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes

Diabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetic Neuropathies
EMD Serono Research & Development Institute, Inc.

Terminated

Next-Gen MS: Feed-forward PRO Data for MS Research

Multiple Sclerosis (MS)

United States
EMD Serono Research & Development Institute, Inc.

Completed

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Carcinoma, Merkel Cell

United States, Spain, Australia, Italy, Germany, France, Japan
ModernaTX, Inc.
Biomedical Advanced Research and Development Authority

Active, not recruiting

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 (TeenCove)

SARS-CoV-2

United States, Dominican Republic
Cytovale, Inc.
Biomedical Advanced Research and Development Authority

Active, not recruiting

SQuISH-COVID: A Pilot Study

COVID-19 | Sepsis

United States
Altimmune, Inc.
Biomedical Advanced Research and Development Authority

Completed

NasoShield in Healthy Adults to Study Safety and Immunogenicity

Healthy Volunteers

United States
EMD Serono Research & Development Institute, Inc.

Completed

CLARITY Extension Study

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Bulgaria, France, Italy, Russian Federation, Turkey, United Kingdom, Estonia, Germany, Latvia, Lithuania, Poland, Austria, Brazil, Canada, Finland, Portugal, Greece, Serbia, Denmark, Ukraine, Saudi Arabia, Lebanon and more
EMD Serono Research & Development Institute, Inc.

Completed

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) (ONWARD)

Multiple Sclerosis

United States, Italy, Russian Federation, Spain
Johnson & Johnson Pharmaceutical Research & Development...
Eisai Inc.

Completed

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

Gastroesophageal Reflux

United States, Belgium, Israel, Poland, Australia, Netherlands, South Africa, Hungary, Bulgaria, Denmark
VA Office of Research and Development
Oncovir, Inc.

Not yet recruiting

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC (HAITEN-ICI)

Stage IV NSCLC

United States
Invirsa, Inc.
Biomedical Advanced Research and Development Authority

Recruiting

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

Acute Infectious Keratoconjunctivitis

United States, Thailand
EMD Serono Research & Development Institute, Inc.

Recruiting

The MS-LINK™ Outcomes Study

Multiple Sclerosis

United States
Visterra, Inc.
Biomedical Advanced Research and Development Authority

Completed

Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A

Influenza

United States, Estonia, South Africa, Bulgaria, Serbia, Ukraine, Latvia
BioNTech Research & Development, Inc.
SciQuus Oncology

Terminated

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

Pancreatic Carcinoma | Tumors That Express CA19-9

United States
ModernaTX, Inc.
Biomedical Advanced Research and Development Authority

Completed

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

Zika Virus

United States, Puerto Rico
ModernaTX, Inc.
Biomedical Advanced Research and Development Authority

Completed

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

Zika Virus

United States
Rowan University
National Development and Research Institutes, Inc.

Completed

Incentives for Internet-based Adherence to SMBG for Teens With T1D

Contingent Versus Noncontingent Incentives

Clinical Trials Sponsored by Centocor Research & Development, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations